Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes

Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes

(2013) D J Baker et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus

(2013) A. Kiyosue et al.   DIABETES OBESITY & METABOLISM

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

(2013) Russell A. Miller et al.   NATURE

Methazolamide Is a New Hepatic Insulin Sensitizer That Lowers Blood Glucose In Vivo

(2012) N. Konstantopoulos et al.   DIABETES

Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

(2012) M. Sjöstrand et al.   DIABETES OBESITY & METABOLISM

Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males

(2012) Ensio Norjavaara et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes

(2012) Elza Muscelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

(2012) Michael J. Waring et al.   MedChemComm

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

(2011) M. Evans et al.   DIABETES OBESITY & METABOLISM

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

(2011) Aurélie Waget et al.   ENDOCRINOLOGY

Sitagliptin: a review

(2011) Sreevidya Subbarayan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092

(2011) Michael J. Waring et al.   MedChemComm

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

(2010) R. A. DeFronzo   DIABETOLOGIA

Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1

(2010) Patricia L. Brubaker   ENDOCRINOLOGY

A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat

(2010) Sumika Ohyama et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Determination of metformin in mouse, rat, dog and human plasma samples by laser diode thermal desorption/atmospheric pressure chemical ionization tandem mass spectrometry

(2010) John G. Swales et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Diet-induced Obesity in Two C57BL/6 Substrains With Intact or Mutant Nicotinamide Nucleotide Transhydrogenase (Nnt) Gene

(2010) Anthony Nicholson et al.   Obesity

Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis

(2009) P. Flatt et al.   CURRENT DRUG METABOLISM

Insulin Therapy for Type 2 Diabetes

(2009) S. G. Swinnen et al.   DIABETES CARE

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

(2009) Kara K. Osbak et al.   HUMAN MUTATION

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Impact of Small-Molecule Glucokinase Activator on Glucose Metabolism and β-Cell Mass

(2008) Akinobu Nakamura et al.   ENDOCRINOLOGY

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of chronic rosiglitazone, metformin and glyburide treatment on β-cell mass, function and insulin sensitivity in mZDF rats

(2007) L. L. Atkinson et al.   DIABETES OBESITY & METABOLISM

Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice

(2007) T. Gorman et al.   DIABETES OBESITY & METABOLISM